The group's goal is to develop new targeted and personalised cancer immunotherapies. To this end, the group combines bioinformatics and molecular research to identify neoantigens and develop cancer vaccines based on these molecules
The Neoantigens and Vaccines against Cancer (NeoVaCan) group performs immunogenomic analyses of solid tumours and liquid biopsies to study the interplay between tumour cells and the immune microenvironment. Multi-omics coupled to functional T-cell-based assays is deployed to obtain a deeper understanding of the host immune response to cancer and to identify immune escape mechanisms.
A main pillar of the group’s work is to identify and characterize neoantigens (mutated peptides expressed only by tumour cells) to be used as targets for immunotherapies, with a special focus on neoantigen vaccines. NeoVaCan is, with the VIC group, co-developing preventive and therapeutic neoantigen vaccines using an in-house virus-like particle (VLP)-based vaccine platform.
-
-
-
Converging and evolving immuno-genomic routes toward immune escape in breast cancer.
Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation.
Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
-
News from the group
